Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04875195 · ClinicalTrials.gov registry record · Phase 2
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
A Phase 2 study of Hodgkin's Lymphoma and Primary Mediastinal Large B-cell Lymphoma (PMBCL), sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 20
- Study locations
NCT04875195 is a Phase 2 study of Hodgkin's Lymphoma and Primary Mediastinal Large B-cell Lymphoma (PMBCL) that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 66 participants, below the 101-participant average among 18 other Hodgkin's Lymphoma trials with a reported enrollment target (35% lower). The trial reports 20 study locations across 18 states.
The verdict
NCT04875195, a Phase 2 study of Hodgkin's Lymphoma and Primary Mediastinal Large B-cell Lymphoma (PMBCL), has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab every six weeks (Q6W).
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
Study Locations (20)
Other
- Fakultni nemocnice Hradec Kralove-IV. interni hematologicka klinika ( Site 0304) - Hradec Králové
- Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0503) - Naples
Moscow
- The National Medico-Surgical Center N.I. Pirogov ( Site 0801) - Moscow
- Moscow City Clinical Hospital S.P. Botkin ( Site 0803) - Moscow
California
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site - Torrance
Louisiana
- Tulane Medical Center ( Site 0110) - New Orleans
Maryland
- Anne Arundel Medical Center-Anne Arundel Oncology and Hematology ( Site 0125) - Annapolis
Paraná
- Hospital Erasto Gaertner ( Site 1703) - Curitiba
São Paulo
- Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1701) - Barretos
Alberta
- Cross Cancer Institute ( Site 0207) - Edmonton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2021-06-07 |
| Est. Completion | 2025-10-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04875195
The ClinicalTrials.gov registry entry for NCT04875195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 18 other Hodgkin's Lymphoma trials with a reported enrollment target (35% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT04875195 reports 20 study locations spanning 18 distinct geographic areas - top geographies include Other, Moscow, California.
Frequently Asked Questions
What is clinical trial NCT04875195 about?
NCT04875195 is a clinical study titled "A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)". The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab every six weeks (Q6W).
What is the current status of trial NCT04875195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2021-06-07. Estimated completion is 2025-10-13.
What conditions does trial NCT04875195 study?
This clinical trial studies the following conditions: Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL).
What interventions are being tested in trial NCT04875195?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04875195?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04875195 being conducted?
This trial has 20 study locations across California, Louisiana, Maryland, Paraná, São Paulo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
RECRUITING · Phase 2
-
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
COMPLETED · Phase 2
-
Reduced Intensity Double Umbilical Cord Blood Transplantation
COMPLETED · Phase 2
-
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
COMPLETED · Phase 2
-
Meloxicam vs Placebo for Mobilization
COMPLETED · Phase 2
-
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
COMPLETED · Phase 2
Explore more on PlainTrial
Hodgkin's Lymphoma
All registered trials for this condition
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.